DocGo Inc. (DCGO) vs Harvard Bioscience, Inc. (HBIO)

A side-by-side comparison of DocGo Inc. and Harvard Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DCGO vs HBIO

growth of $100 · dividends reinvested · last 6y
DCGO -96.5% (-42.7%/yr)HBIO -79.7% (-23.3%/yr)HBIO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$4$20
DCGO HBIO

DCGO vs HBIO: by the numbers

  • •HBIO is the larger company ($39M vs $36M market cap).
  • •Both run net losses; HBIO's is the smaller (-11.86% vs -65.29% net margin).
  • •DCGO grew revenue faster over the past five years (11.63% vs -4.62% CAGR).

Metrics side by side

Valuation

MetricDCGOHBIO
P/S ratio0.120.44
P/B ratio0.315.19
EV / EBITDAN/A10.53

Profitability

MetricDCGOHBIO
Gross margin30.12%58.16%
Operating margin-27.67%1.17%
Net margin-65.29%-11.86%
ROE-161.63%-140.36%
ROIC-89.44%1.99%

Growth (annualized)

MetricDCGOHBIO
Revenue CAGR (5Y)11.63%-4.62%
Total return CAGR (5Y)-48.40%-34.33%

Frequently asked

Which has grown faster, DCGO or HBIO?
Over the past five years, DCGO grew revenue faster — DCGO at a 11.63% CAGR versus HBIO at -4.62%.
How have DCGO and HBIO total returns compared?
Over the past 5 years, DCGO delivered -48.40% and HBIO delivered -34.33% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.